Check for updates

RESEARCH ARTICLE

Does the mouse tail vein injection method provide a good model of lung cancer? [version 1; peer review: 2 approved]

Nensi Shrestha, Zabeen Lateef, Orleans Martey, Abigail R. Bland, Mhairi Nimick, Rhonda Rosengren, John C. Ashton

Department of Pharmacology and Toxicology, University of Otago, Dunedin, 9054, New Zealand

V1 First published: 15 Feb 2019, 8:190
<https://doi.org/10.12688/f1000research.17964.1>
 Latest published: 15 Feb 2019, 8:190
<https://doi.org/10.12688/f1000research.17964.1>

Abstract

Lung cancer drug development requires screening in animal models. We aimed to develop orthotopic models of human non-small lung cancer using A549 and H3122 cells delivered by tail vein injection. This procedure has been used previously for a mouse lung cancer (Lewis lung carcinoma) and as a model of human breast cancer metastasis to lung. We report that the procedure led to poor animal condition 7-8 weeks after injection, and produced lesions in the lungs visible at necropsy but we were unable identify individual cancer cells using immunohistochemistry. We conclude that if this method is to produce a model that can be used in drug experiments, improvements are required for cancer cell detection post mortem, such as by using of a fluorescently tagged human lung cancer cell line.

Keywords

human cells, lung cancer, mouse model, tail vein

Open Peer Review

Approval Status

	1	2
version 1
15 Feb 2019	view	view
1. Malcolm Tingle , University of Auckland, Auckland, New Zealand		
2. Giulio Francia , University of Texas at El Paso, El Paso, USA		

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: John C. Ashton (john.ashton@otago.ac.nz)

Author roles: Shrestha N: Data Curation, Formal Analysis, Investigation, Methodology, Visualization, Writing – Review & Editing; Lateef Z: Investigation, Supervision; Martey O: Investigation; Bland AR: Investigation; Nimick M: Investigation; Rosengren R: Conceptualization, Investigation, Writing – Review & Editing; Ashton JC: Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Methodology, Resources, Supervision, Writing – Original Draft Preparation

Competing interests: No competing interests were disclosed.

Grant information: This work was funded by a grant from the Otago Medical Research Foundation, Grant No. AG 327. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Shrestha N *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Shrestha N, Lateef Z, Martey O *et al.* Does the mouse tail vein injection method provide a good model of lung cancer? [version 1; peer review: 2 approved] F1000Research 2019, 8:190 <https://doi.org/10.12688/f1000research.17964.1>

First published: 15 Feb 2019, 8:190 <https://doi.org/10.12688/f1000research.17964.1>

Introduction

Lung cancer causes more deaths worldwide than any other cancer in both males and females¹. Good animal models of lung cancer are essential if treatments are to improve, but there are disadvantages to existing models of lung cancer. Non-small cell lung cancer (NSCLC) comprises approximately 85% of all lung cancer², and therefore represents the lung cancer subtype where good models are most needed.

Mouse models of lung cancer fall into several categories. The first division that can be made is whether the cancer cells are of mouse or human origin. Cancer cells of mouse origin may be grafted onto a host mouse, or induced in tissues by genetic modification, chemical means, or spontaneously. Neither fully recapitulates human cancer. To study the effects of a drug on human cancer in mouse models requires cancer cell xenografts in immunocompromised mice, such as nude or severely immune compromised (SCID) mice. This may be as a solid tumour in the mouse flank or for increased pharmacokinetic validity, an orthotopic model where cells are directly grafted into the lungs. Grafting cancer cells into mouse lungs may take place by several different methods. The cells may be directly injected into the lung, (i.e., by intrathoracic implantation via puncture³), or the cells may be introduced into the airways of the mouse, causing a bronchial tumour⁴.

An advantage of intrathoracic implantation, by direct puncturing through the intercostal space to lung parenchyma, is that it avoids thoracotomy or intubation, but the method is disadvantaged by the risk of pneumothorax, intrathoracic haemorrhage and haemoptysis³. Methods of bronchial implantation without surgical thoracotomy have been developed⁴, but these are disadvantaged by a risk of death during cancer cell inoculation. We therefore experimented with another method of cancer cell inoculation in the mouse lung; engraftment via vascular delivery and pulmonary entrapment. This method has been successfully used to create lung tumour nodules in the lungs of immunocompetent mice using Lewis lung carcinoma cells⁵, but to our knowledge has not been used to study lung cancer using human lung cancer cells in immunocompromised mice. We therefore carried out a study using SCID mice, inoculating them via tail vein injection either with A549 or H3122 human adenocarcinoma cells. A549 cells are sensitive to Kirsten sarcoma virus protein (Kras) inhibition⁶ and the H3122 cells are sensitive to anaplastic lymphoma kinase (ALK) inhibition⁷.

Methods

Cell culture

Human lung adenocarcinoma cells (A549) were maintained in complete growth media (RPMI1640, ThermoFisher, USA) with 2% heat-inactivated foetal bovine serum (FBS, Sigma-Aldrich, NZ). Human NSCLC adenocarcinoma cells harbouring the EML4-ALK variant one (H3122) were maintained in 5% FBS RPMI 1640. All cell lines were also maintained in 2 mM L-glutamine and 1% streptomycin/penicillin (100 µg/mL, Sigma-Aldrich, AU), and grown in a humidified incubator at 5% CO₂, 95% O₂ and 37°C. At 80–90% confluence, cells were passaged with 1X TrypLE (A459 and H3122 cell lines, ThermoFisher, NZ).

Animal housing and care

Male immunocompromised SCID mice were purchased from Animal Resources Centre, Australia. All animal experiments were performed after approval by the University of Otago (AEC #9/17). SCID mice were housed in pathogen-free condition with sterile woodchip bedding supplied with sterile food (Reliance rodent diet, Dunedin, NZ) and water. Mice were kept in a room maintained at temperature of 21–24°C on a scheduled 12 h light/dark cycle.

Tail vein injection

A total of 48 male 12-week-old SCID mice, 20–30 g in weight, were divided into two identical experiments comprised of 24 mice each. As this is a method development study, no data existed with which to carry out a power analysis. Instead, we designed our experiment based on the maximum number of SCID mice we could import in one batch, dividing the mice into two groups in order to trial two different human adenocarcinoma cell lines. Mice were then sub-divided equally between 3-, 5-, and 8-week duration experiments. Two mice were not injected with cells. As this was not a hypothesis test study, we did not allocate mice to groups according to a randomization protocol, but assigned mice to groups sequentially by individual cage that they were housed in (allocated independently by animal technicians). In each experiment, mice were restrained and injected into the medial tail vein (Figure 2) with either 1x10⁵ A549 cells or 1x10⁵ H3122 cells suspended in 100 µl of phosphate buffer saline (PBS). Mice were weighed daily and monitored for mobility, respiratory distress, and signs of pain daily for up to 8 weeks. A weight loss of more than 20% was deemed to be unacceptable and would lead to early sacrifice of the mouse. At the end of 3 weeks in each experiment 4 mice from each group (i.e., 8 mice across the two repeats of the experiment) were euthanized by CO₂ exposure and perfused with isotonic PBS followed by 10% formalin. Organs were rapidly removed, weighed and kept in 10% formalin for 48 h followed by 30% starch solution for 24 h at 4°C. The organs were embedded in Optimal cutting temperature compound (OCT) and snap-frozen in liquid nitrogen. Organs removed in this way were brain, kidney, spleen, liver, lungs, heart, and testes. Lungs were quickly photographed prior to freezing and fixation. This was repeated for another 4 mice in each group at 5 weeks and 7–8 weeks following injection, and compared with lungs taken from SCID mice that were not injected with lung cancer cells, from another experiment.

Histology and immunohistochemistry

Frozen, fixed lungs were embedded in OCT and 6-µm sections cut and mounted on poly-L-lysine-treated frosted slides. Mounted sections were either stained with haematoxylin QS (H-3404, Vector laboratories, USA) and eosin (Sigma Aldrich, USA) or probed with antibodies for ALK (Cat# 3633, RRID:AB_11127207, Cell Signaling Technology, USA phospho-ALK (Cat# 6962, RRID:AB_10828357, Cell Signaling Technology, USA) (H3122 cell injected mice only) or human Ki67 Cat# M7249, RRID:AB_2250503, (Dako, Denmark and Abcam, UK).

Lung sections were fixed with acetone and methanol (1:2) solution for 10 min and were incubated with haematoxylin followed

by eosin. Excess of eosin was removed by rinsing in 95% ethanol and slides were dehydrated in a series of 95%–100% ethanol. The sections were then soaked in xylene and mountant in DPX mounting solution.

For immunohistochemistry, lung sections were fixed with acetone for 10 min at room temperature and then treated with 0.3% of hydrogen peroxide in methanol for 20 min. Prior to incubation with antibodies, antigen retrieval was performed by boiling at 95°C in either water bath or in a decloaker chamber (Biocare Medical, USA) in citrate buffer (10 mM citric acid, 0.05% Tween-20) pH 6 for 20–30 min (Ki67) and EDTA buffer (1 mM EDTA and 0.05% Tween 20) pH 9 for 30–40 min (ALK/p-ALK). A range of blocking techniques were also trialled, including avidin-biotin blocking for biotinylated secondary antibodies. After incubation with primary antibodies overnight, washed slides were then incubated for up to 2 h with either goat anti-Rabbit IgG, HRP conjugate (Cat# 401353-2ML, RRID:AB_10690659, Millipore, US) or for up to 45 min with biotinylated goat anti-rabbit IgG (Cat# 550338, RRID:AB_393618BD, Biosciences, USA) for subsequent labelling with HRP-conjugated streptavidin (Cat# PA5-54066, RRID:AB_2639134, Thermo Fisher Scientific, USA). Following washing, all slides with stained with 3,3'-diaminobenzidine (DAB, BD Pharmingen, USA). Coverslip mounted sections were then examined by two examiners blinded to the treatment groups using a Nikon RM229 microscope.

Statistical analysis

Weight gain over time was analysed using linear regression. Organ weights at necropsy were analysed using one-way ANOVA with Bonferroni post hoc tests. All statistical analyses were carried out using GraphPad Prism v7.

Results

Mouse weight

Mice that had been inoculated with A549 human lung cancer cells were slightly heavier than mice inoculated with H3122 cells, as shown by a 1.8 g difference in weight at baseline (Figure 1; $F = 884.5$, $DF_n = 1$, $DF_d = 111$, $P < 0.0001$, linear regression). However, this gap was maintained during the experiment, such that mice inoculated with A549 cells showed no difference in rate of weight gain from those inoculated with H3122 cells (0.068 g/day and 0.075 g/day, respectively, a non-significant difference, $F = 2.549$, $DF_n = 1$, $DF_d = 110$, $P = 0.1133$, linear regression). However, at over 50 days after inoculation, mice began to show signs of distress, manifested by hunched posture, immobility, rough coats, and laboured breathing. One mouse had proptosis (protruding eyes); this mouse was sacrificed, and all other mice were then sacrificed within a day (i.e., mice in the 8-week group were sacrificed in the 8th week after injection). At this point, mice inoculated with A549 cells appeared to lose weight by 0.08 g/day, although this was not significant ($F = 1.52$, $DF_n = 1$, $DF_d = 6$, $P = 0.2638$, linear regression). Raw values for body weight, alongside all other raw data, are available on figshare¹².

Organ weight

At necropsy, organs were weighed; there were no significant ($P > 0.05$, one-way ANOVA with Bonferroni post hoc tests)

differences between organ (including lung) weights taken at weeks 3, 5, or 8. (Figure 2). However, examination of the lungs showed that numerous superficial white opacities began to appear by week 5, minimally apparent in week 3 mice lungs and absent in a control mouse (no cancer cells injected) (Figure 3A-C and Figure 4A-C).

Histological and immunochemical staining

Haematoxylin and eosin staining of the lungs did not show tumour cell nodules with distinct edges (Figure 3 and Figure 4) consistent with the dispersed cancer cell pattern observed by Rashid et al.⁸ using breast cancer cells. Notably, in earlier weeks for both lung cancer cell types, lung sections consisted of a sparse network of bronchioles, and alveolar ducts and sacs with infrequent areas where cells were aggregated in the parenchyma (Figure 3–Figure 4). These areas were more extensive by week 5, and increased through to week 8.

However, we were unable to confirm that areas of cellular density corresponded to cancer cells, as we were unable to obtain positive staining for tumour cell markers using immunohistochemistry. In mice inoculated with ALK-positive H3122 cells, we did not find specific staining with either ALK or p-ALK antibodies (with secondary antibody only sections showing high amounts of non-specific staining). Similarly, when we looked in lung sections from mice inoculated with either cell, we could not distinguish primary antibody specific from non-specific labelling for any human cell marker, including Ki67. Although we used a range of antigen-retrieval techniques and different secondary antibodies (both directly conjugated to HRP, and biotinylated) we could not detect any primary antibody specific labelling in inoculated mouse lungs compare to control mouse lungs. There are at least two possible reasons for this. First, cancer cells may have been present but not detected by immunolabelling methods sufficiently due to low concentrations of secondary antibody. This may be because of over-fixation with formalin. To test this hypothesis

Figure 1. Body weight of SCID mice injected with A549 or H3122 human lung adenocarcinoma cells via the tail vein over 8 weeks. Data points are means and error bars are SEM. Up to week three there were four mice for each cell type. Four mice were then sacrificed, and another four mice at week 5.

Figure 2. Organ weights of SCID mice injected with A549 or H3122 human lung adenocarcinoma cells via the tail vein at 3, 5, and 8 weeks after injection. Bar heights are means and error bars are SEM (n=4).

Figure 3. Gross appearance and histology of the lungs of SCID mice injected with H3122 human lung adenocarcinoma cells via the tail vein. (A-C) lungs from mice injected with cells at 3 (A), 5 (B), and 8 (C) weeks after cell injection. Note the white patches on the lungs, which appeared by week 5; D-F. Haematoxylin and Eosin stain of lungs from mice at 3 (D), 5 (E), and 8 (F) weeks after cell injection using a 10x objective. Squares and arrows indicate areas of high cell density; (G-I) Area shown in insets from panels (D-F) respectively, using a 20x objective. (J-L) Area shown in insets from images (D-F), respectively, using a 40x objective. Scale bars: D-I 100 μ m; J-L 50 μ m.

Figure 4. Gross appearance and histology of the lungs of SCID mice injected with A549 human lung adenocarcinoma cells via the tail vein. (A) lungs from a mouse that did not receive a cancer cell injection; B-C. lungs from mice injected with cells at 5 (B), and 8 (C). Note the white patches on the lungs, which appeared by week 5 (as for H3122 cells above). (D-F) Haematoxylin and Eosin stain of lungs from mice at 3 (D), 5 (E), and 8 (F) weeks after cell injection using a 10x objective. Squares and arrows indicate areas of high cell density. (G-I) Area shown in insets from images D-F respectively, using a 20x objective. (J-L) Area shown in insets from images (D-F) using a 40x objective. Scale bars: D-I 100 μ m; J-L 50 μ m.

will require a repeat of the experiment, testing a range of fixation methods or other visualisation methods (such as fluorescently labelling cells). As SCID mice are only available by importation in New Zealand, the country in which these experiments were carried out, this was not possible in the current study. But it is also possible that cancer cells have failed to engraft in lung parenchyma, such that cellular aggregations in haematoxylin and eosin-stained sections were either artefacts or else pathological features secondary to embolism. This second interpretation, however, is difficult to reconcile with the time-dependent appearance of superficial lesions on the lungs, loss of body condition, and increasing density of cells in lung histology, most apparent 8 weeks after tumour cell injection.

Discussion

Lung cancer drug development is a difficult process, and using mouse models to screen novel drugs is a critical part of it. Development of new models is therefore part of the process of lung cancer drug development. We carried out these experiments in order to test whether tail vein injection of two commonly used human lung adenocarcinoma cell lines could recapitulate aspects of human lung cancer, to facilitate efficient drug testing. This procedure has successfully been used previously only with one mouse lung cancer cell line (Lewis lung carcinoma)⁵, where female C57 immunocompetent mice, age 6 weeks, were tail vein injected with 2×10^6 cells in 100 μ l PBS). However, although our procedure did lead to poor animal condition in SCID mice 7–8 weeks after injection, as well as lesions in the lungs apparent at necropsy and histological differences, we were unable to identify individual cancer cells using immunohistochemistry. However, we do not yet conclude because of this that a useful model of lung cancer may not be produced by this method.

The pathological consequences of the tumour cell injection are consistent with thromboembolism, with areas of apparent hypoxia on the lungs at necropsy. In other types of cancer, tail vein injection has tended to lead to sudden death due to a thromboembolism. This and the lack of a more gradual progression of tumour burden has led to criticism of tail vein injection

as a model of breast cancer metastasis⁸. Cancer cell injection into any blood vessel is potentially embolic⁹, and thromboembolism is a significant cause of death in human lung cancer¹⁰, subsequent to the development of tumour nodules. Thus, due to the lack of visible lung cancer nodules using the tail vein injection method, the sudden decline in the mice (at 7–8 weeks after injection), the signs of ischaemia in mouse lungs beginning at week 5, but the difficulty in detecting individual cancers in our experiments, we conclude that the model requires further development if it is to be of value in drug development. We outline a strategy for this in our concluding paragraph below.

First, confirmation of hypoxic lesions in the lungs could be ascertained by tetrazolium chloride staining in fresh lung slices¹¹. Second, the structure of the lung is such that relatively strong fixation methods were required to ensure good morphology—more so than for most other tissues in our experience—which can compromise antigen exposure. We aim to overcome this problem in a future experiment through use of a fluorescently-tagged human lung cancer cell line. This approach will facilitate detection of individual cancer cells (by fluorescence microscopy or flow cytometry). Notably, in the study referenced above, Lewis lung carcinoma cells were labelled with GFP, and were thereby visualised by fluorescence microscopy in dissected lung tissue⁵.

Data availability

Raw data on body and organ weights for each mouse, alongside uncropped images of the lungs of mice injected with each cell type, are available on figshare. DOI: <https://doi.org/10.6084/m9.figshare.7633508.v1>¹².

Grant information

This work was funded by a grant from the Otago Medical Research Fund, Grant No. AG 327.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Islami F, Torre LA, Jemal A: **Global trends of lung cancer mortality and smoking prevalence.** *Transl Lung Cancer Res.* 2015; 4(4): 327–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Gridelli C, Rossi A, Carbone DP, *et al.*: **Non-small-cell lung cancer.** *Nat Rev Dis Primers.* 2015; 1: 15009.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Liu X, Liu J, Guan Y, *et al.*: **Establishment of an orthotopic lung cancer model in nude mice and its evaluation by spiral CT.** *J Thorac Dis.* 2012; 4(2): 141–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Nakajima T, Anayama T, Matsuda Y, *et al.*: **Orthotopic lung cancer murine model by nonoperative transbronchial approach.** *Ann Thorac Surg.* 2014; 97(5): 1771–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Zhao M, Suetsugu A, Ma H, *et al.*: **Efficacy against lung metastasis with a tumor-targeting mutant of *Salmonella typhimurium* in immunocompetent mice.** *Cell Cycle.* 2012; 11(1): 187–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Mou H, Moore J, Malonia SK, *et al.*: **Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis.** *Proc Natl Acad Sci U S A.* 2017; 114(14): 3648–3653.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Shaw AT, Engelman JA: **ALK in lung cancer: past, present, and future.** *J Clin Oncol.* 2013; 31(8): 1105–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Rashid OM, Nagahashi M, Ramachandran S, *et al.*: **Is tail vein injection a relevant breast cancer lung metastasis model?** *J thorac dis.* 2013; 5(4): 385–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

9. Schuh JC: **Trials, tribulations, and trends in tumor modeling in mice.** *Toxicol Pathol.* 2004; **32**(suppl 1): 53–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Chew HK, Davies AM, Wun T, *et al.*: **The incidence of venous thromboembolism among patients with primary lung cancer.** *J Thromb Haemost.* 2008; **6**(4): 601–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Linsell O, Ashton JC: **Cerebral hypoxia-ischemia causes cardiac damage in a rat model.** *Neuroreport.* 2014; **25**(10): 796–800.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Ashton J, Shrestha N: **Does the mouse tail vein injection method provide a good model of lung cancer?** For F1000Research. *figshare.* Files. 2019.
<http://www.doi.org/10.6084/m9.figshare.7633508.v1>

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 29 July 2019

<https://doi.org/10.5256/f1000research.19647.r50732>

© 2019 **Francia G.** This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Giulio Francia

Border Biomedical Research Center, University of Texas at El Paso, El Paso, TX, USA

This is a neat paper describing tail vein injection to attempt to generate an *in vivo* model of lung cancer in mice.

It would be helpful if the authors explain why they chose to use male SCID mice, and not female mice. They should also mention that PCR analysis of the lungs could be one way to look for potential metastases (by amplification of sequences that are human-specific).

I think it would be helpful to include a side by side comparison (maybe a table?) of the tail vein results and the models mentioned in the intro, or results from other experiments that have established models using the cell lines mentioned in this study.

They mention non-small cell lung cancer is the most prevalent subtype of lung cancer, but don't discuss how the tail vein injection method could potentially model this specific type of lung cancer. The paper mentions intrathoracic implantation. Have the authors tried this method or are they merely stating it is an alternative option? Are the results comparable to the tail vein injection? They don't state what size needle they use to inject in the tail vein.

The authors could mention that a more laborious attempt (not without drawbacks) would be spontaneous metastasis assays, by first injecting a primary tumor – followed by surgical resection – and then allowing several weeks for the development of spontaneous metastases.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: metastasis

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 26 March 2019

<https://doi.org/10.5256/f1000research.19647.r45833>

© 2019 Tingle M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Malcolm Tingle

Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

The current study has attempted to use a relatively straightforward approach to determine whether injection of adenocarcinoma cells via a tail vein in mice can produce a viable model for lung cancer, presumably with a view to screening potential therapies for human disease. This appears as a reasonable aim, given that the current models are far from perfect, with the potential for a high failure rate of animals through technical difficulties with intrathoracic implantation. Although the current study is limited in its size and scope, it has produced results that are worthy of publication, in part because the model does not appear to have been as successful as perhaps the authors had initially hoped and that along the way there are clear welfare issues that should feature in any ethical harm: benefit consideration by an animal ethics committee.

One of the key aims of this type of study is to mimic as closely as possible human disease. Unfortunately, the authors report that despite clear pathological changes occurring in the lungs of the animals, it was not possible to identify the presence of the cells of interest. Without further work-up, this would render the current strategy as potential for the screening of selective therapeutic approaches. The possibility for further workup may be limited by the fact that the tail injection of these adenocarcinoma cells appeared to produce lung damage that adversely impacted on the health of the animals, resulting in a decision to euthanise the animals. In this respect, the authors are to be congratulated on not merely adhering to some obvious metric, such as body weight, but also taking into account more subjective measures. One can only assume that 'laboured breathing', presumably as a consequence of the thromboembolism, was in fact quite marked, although the fact that animals did not suffer dramatic weight loss (Figure 1) indicates that they were still eating, and more importantly, not becoming dehydrated. To a large extent, any further attempts to develop this model will be limited by ethical consideration and oversight as

science.

The manuscript is succinct and given the findings of this preliminary study, the conclusions seem appropriate. However, I would recommend that the authors change the term 'sacrifice', since it really has no place in scientific literature, since it does not implicitly infer that the animal was killed humanely. The authors use the terms as if synonyms, *"A weight loss of more than 20% was deemed to be unacceptable and would lead to early sacrifice of the mouse. At the end of 3 weeks in each experiment 4 mice from each group (i.e., 8 mice across the two repeats of the experiment) were euthanized by CO₂ exposure"* However, there may be marked differences between the religious sacrifice of an animal and accepted species-specific practice of euthanasia for animals in scientific experiments covered by legislation.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Adverse drug reactions; toxicology; species differences in xenobiotic disposition, kinetics and toxicity

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research